NxStage Medical Received its Third Buy in a Row

By Jason Carr

After BTIG and Piper Jaffray assigned a Buy rating to NxStage Medical in the last month, the company received another Buy, this time from Northland Securities. Analyst Suraj Kalia reiterated a Buy rating on NxStage Medical (NASDAQ: NXTM) today and set a price target of $35. The company’s shares opened today at $26.60.

According to TipRanks.com, Kalia is a 3-star analyst with an average return of 3.9% and a 54.2% success rate. Kalia covers the Healthcare sector, focusing on stocks such as Xtant Medical Holdings, Edwards Lifesciences, and Intuitive Surgical.

Currently, the analyst consensus on NxStage Medical is Strong Buy and the average price target is $33.50, representing a 25.9% upside.

In a report issued on March 21, Jefferies also reiterated a Buy rating on the stock with a $38 price target.

Based on the recent corporate insider activity of 68 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NXTM in relation to earlier this year. Last month, Craig Moore, a Director at NXTM sold 1,000 shares for a total of $27,930.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

NxStage Medical, Inc. operates as a medical device company which manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. Its primary product, the NxStage System One, was designed to satisfy an unmet clinical need for a system that can deliver the therapeutic flexibility and clinical benefits associated with traditional dialysis machines in a smaller, portable, easy to use form that can be used by healthcare professionals and trained lay users alike in a variety of settings, including patient homes, as well as more traditional care settings such as hospitals and dialysis clinics. The company also markets its product NxStage System One to hospitals for treatment of acute kidney failure and fluid overload. The company operates through the following segments: System One, In-Center and Services. The System One segment engages in the sale and rental of the System One and PureFlow SL equipment and the sale of disposable products in the home and critical care markets. The In-Center segment sells blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers and needles for apheresis. The Services segment includes revenues from dialysis services provided to patients at its recently opened NxStage Kidney Care dialysis centers. NxStage Medical was founded by Jeffrey H. Burbank in December 1998 and is headquartered in Lawrence, MA.